A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

This study tests a new targeted drug called HS-10365 specifically for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic alteration called a RET gene fusion — a change where the RET gene abnormally joins with another gene, causing uncontrolled cancer growth. **You may be eligible if...** - You are 18 or older with advanced or metastatic lung cancer (NSCLC) confirmed by biopsy - Your tumor has a confirmed RET gene fusion - Your cancer is not suitable for surgery - You have at least one measurable tumor on imaging - Your life expectancy is more than 12 weeks - You have not had prior treatment for metastatic lung cancer **You may NOT be eligible if...** - You have had prior treatment targeting the RET gene - You have had prior systemic (body-wide) therapy for metastatic disease - Your cancer has another known primary driver mutation (like EGFR, ALK) - You have active or uncontrolled brain metastases - You have active autoimmune disease or a serious uncontrolled infection - You have serious heart problems, nausea that cannot be controlled, or severe GI disease - You are pregnant or breastfeeding - You have epilepsy, dementia, or significant nerve damage Talk to your doctor to see if this trial is right for you.